XCOVERY
PharmaXCOVERY is a pharmaceutical company focused on Oncology. Key products include ENSACOVE.
FDA Novel Drug Designations
(2024)See 1 novel approval →
XCOVERY's Key Drugs
XCOVERY's core commercial portfolio centers on ENSACOVE, spanning Oncology — its most strategically important drugs approved in the last 15 years.
XCOVERY's Recent FDA Approvals
XCOVERY secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
XCOVERY's Therapeutic Areas
XCOVERY's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
XCOVERY's Top Competitors
XCOVERY's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
XCOVERY Pipeline Snapshot
XCOVERY has 3 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ENSACOVE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-12-18
- Latest
- 2026-02-26
- Applications
- 1